Urothelial Cancer
CA244-0012, IZABRIGHT-BLADDER01: A RANDOMIZED, OPEN-LABEL, PHASE 2/3 TRIAL OF IZALONTAMAB BRENGITECAN VERSUS PLATINUM-BASED CHEMOTHERAPY FOR METASTATIC UROTHELIAL CANCER IN PARTICIPANTS WITH DISEASE PROGRESSSION ON OR AFTER AN IMMUNOTHERAPY-BASED TREATMENT
- Details
ClinicalTrials.gov ID:
NCT07106762
Diagnosis Type:
NA
USOR Number:
- Address
,
P: